Vendor Intelligence Report: NextechLabs

Published 13 Jun 2026. 24-page investigative report on who is behind NextechLabs: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 31 Finnrick lab tests, NextechLabs records 22 passes and 9 failures, for a 71% overall pass rate. The result is mixed rather than uniformly weak: Retatrutide and Ipamorelin are the strongest signals, while BPC-157 and CJC-1295 are materially unfavorable. Buyers should not extrapolate a good Retatrutide record across the catalog, especially because ratings narrow or collapse under stricter grading.

The public operating record looks young and unsettled. The domain and storefront activity predate the Delaware corporation, and the reviewed Delaware record lists the entity as not in good standing. Website policies point to a Delaware formation-service address, a separate registered agent, and a Florida postal return point instead of a verifiable operating site; no public owner or principal was identified.

NextechLabs’ posted COAs come from a real ISO 17025 laboratory, which is a meaningful positive. The narrower issue is scope: the COAs reviewed document HPLC purity and quantity, not endotoxin or sterility testing. Several late-2025 COA images also sit in 2024 WordPress upload paths, creating a provenance and backdating concern the report walks through exhibit by exhibit.

Fulfillment and recourse remain unresolved. The site claims U.S. packing and shipping, while a return-policy address points to a postal facility and a verified review alleges China-origin shipping. Card payment appears to preserve some dispute route, but Zelle materially weakens buyer protection.

Inside the full report:

  • Product-specific Finnrick pass/fail analysis, methodology-divergence charts, and Appendix A laboratory data for all 6 products
  • Dated timeline comparing domain registration, storefront launch, Delaware incorporation, COA dates, and archive captures
  • Delaware filing, registered-agent records, Terms-page address, and Florida USPS return-address assessment
  • Vanguard Laboratory COA review covering test scope, missing endotoxin/sterility categories, and WordPress upload-path anomalies
  • Trustpilot review-profile analysis, negative-review allegations, and community-response checks
  • Payment and buyer-recourse review covering card routing, Zelle, and refund-policy artifacts

Risk assessment

  • BPC-157 and CJC-1295 product-quality risk — high: Finnrick data is strongest for Retatrutide and Ipamorelin, but BPC-157 is 2 pass / 5 fail with a 42.54% rating and CJC-1295 is 2 pass / 2 fail with a 31.88% rating.
  • Missing endotoxin/sterility testing on vendor COAs — high: Vendor COAs inspected for Retatrutide, Semaglutide, Tirzepatide, GHK-Cu, and BPC-157/TB-500 report HPLC purity/quantity only; no endotoxin or sterility testing is documented.
  • Fulfillment-location and custody-chain uncertainty — medium: FAQ claims US packing/shipping, but returns point to an undisclosed box at a Delray Beach USPS facility and one verified Trustpilot review alleges China shipping with about one-month delivery.
  • Corporate/ownership opacity and good-standing concern — medium: NEXTECH LABS, INC. formed in Delaware on August 13, 2025, is listed as not in good standing, and no owners/personnel or true operating address were identified.
  • COA provenance/backdating concern — medium: COAs dated October-November 2025 are hosted in /2024/04, /2024/06, /2024/07, and /2024/09 WordPress paths, consistent with backdating or nonstandard upload handling.
  • Marketing and review-integrity concern — medium: The 150K Happy Customers and pioneer claims are unsupported by the dated record, and Trustpilot shows a bimodal pattern consistent with review manipulation.
  • Payment-recourse risk — medium: Zelle is offered alongside card payments; Zelle provides no chargeback path if product is wrong, missing, or not refunded.